A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT07772531
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- BMS-986511 — DRUGSpecified dose on specified days
- Placebo — DRUGSpecified dose on specified days
Study Details
A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder
Key Dates
- First listed
- Aug 19, 2026
- Start date
- Oct 30, 2026
- Status verified
- Aug 2026
- Primary completion
- Nov 6, 2028
- Completion
- Nov 6, 2028
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: BMS-986511: Dose A
- Experimental: BMS-986511: Dose B
- Experimental: Placebo
Primary Outcome Measure
Mean change from baseline in Hamilton Depression Rating Scale -17 Item (HDRS-17) total score [ Time Frame: Up to Day 57 ]
Central Contacts
- BMS Clinical Trials Contact Center www.BMSClinicalTrials.com855-907-3286
- First line of the email MUST contain NCT # and Site #.
Locations (20)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Local Institution - 0144 | Phoenix | Arizona | 85012 | Site 0144 |
| Local Institution - 0038 | Little Rock | Arkansas | 72211 | Site 0038 |
| Local Institution - 0047 | Rogers | Arkansas | 72758 | Site 0047 |
| Local Institution - 0046 | Garden Grove | California | 92845 | Site 0046 |
| Local Institution - 0042 | Glendale | California | 91206 | Site 0042 |
| Local Institution - 0071 | Lemon Grove | California | 91945 | Site 0071 |
| Local Institution - 0079 | Oakland | California | 94607 | Site 0079 |
| Local Institution - 0050 | Upland | California | 91786 | Site 0050 |
| Local Institution - 0007 | Jacksonville | Florida | 32256 | Site 0007 |
| Local Institution - 0024 | Orlando | Florida | 32801 | Site 0024 |
| Local Institution - 0044 | Gaithersburg | Maryland | 20877 | Site 0044 |
| Local Institution - 0075 | Boston | Massachusetts | 02135 | Site 0075 |
| Local Institution - 0041 | Cedarhurst | New York | 11516 | Site 0041 |
| Local Institution - 0069 | Mount Kisco | New York | 10549 | Site 0069 |
| Local Institution - 0121 | Staten Island | New York | 10312 | Site 0121 |
| Local Institution - 0083 | Cincinnati | Ohio | 45219 | - |
| Local Institution - 0086 | Columbus | Ohio | 43210 | Site 0086 |
| Local Institution - 0027 | Oklahoma City | Oklahoma | 73112 | Site 0027 |
| Local Institution - 0016 | Dallas | Texas | 75231 | Site 0016 |
| Local Institution - 0003 | Everett | Washington | 98201 | Site 0003 |
Find similar trials in Phoenix, AZ
By condition
By specialty
Related Studies
- Study of Neuro-Cognitive Correlates of Pediatric Anxiety DisordersPHASE2 · Recruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland
- Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderPHASE1 · Recruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland
- DBS for DepressionRecruiting · Baylor College of Medicine · Dallas, Texas
- A Phase I/II Study of PDC-1421 for Treating Depression in Cancer PatientsPHASE1/PHASE2 · Not Yet Recruiting · BioLite, Inc. · Los Angeles, California